A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
A phase 2 trial of Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.
Overview
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT07465757 by Puma Biotechnology, Inc., with 50 participants planned, started 2026-09-30 and due to reach its primary completion in 2028-03-31. Interventions recorded: Alisertib, Alisertib, Alisertib, Alisertib, Alisertib. Conditions listed: Small Cell Lung Cancer ( SCLC ). No results are recorded here; the registry entry is the source.
Setting
A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
Phase
Phase 2
Sponsor
Puma Biotechnology, Inc.
Registry
Enrolled
50
Similar pages
not linked directly; found by shared links- TrialA Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Shares Alisertib, Puma Biotechnology, Small-cell lung cancer.
- TrialA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Shares Alisertib, Puma Biotechnology.
- TrialAn Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
- TrialA Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer
- TrialA Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287